Mechanisms of plaque stabilization with statins (Q35077211)

6 August 2017

1 reference

title

Mechanisms of plaque stabilization with statins (English)

1 reference

6 August 2017

1

Peter Libby

1 reference

6 August 2017

2

Masanori Aikawa

1 reference

PubMed ID

12615292

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

American Journal of Cardiology

6 August 2017

1 reference

6 August 2017

91

1 reference

6 August 2017

4B-8B

1 reference

6 August 2017

4A

1 reference

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Current perspectives on statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Current concepts of the pathogenesis of the acute coronary syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Plaque changes and arterial enlargement in atherosclerotic monkeys after manipulation of diet and social environment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Dietary lipid lowering reduces tissue factor expression in rabbit atheroma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Atherosclerosis. the road ahead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Isoprenoids as mediators of the biological effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Inflammation and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903267-8

10.1016/S0002-9149(02)03267-8

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12615292